Literature DB >> 31578079

How would China achieve WHO's target of eliminating HCV by 2030?

Mingyang Li1, Hui Zhuang1,2, Lai Wei3.   

Abstract

Introduction: Hepatitis C virus (HCV) infection is a major global health concern on the rise, prompting unprecedented efforts by the World Health Organization (WHO) to eliminate this epidemic by 2030. Being the country with the largest HCV-infected population in the world, China has been faced with a general lack of awareness for HCV, low treatment uptake and subpar collaborations among healthcare providers and stakeholders. Areas covered: This review discusses the epidemiological situations of HCV infection and the challenges in HCV management in China. This review also explores micro-elimination strategies in China, identifying potential sub-populations for concerted efforts in eliminating HCV. As DAAs are increasingly recognized as a more effective alternative to traditional regimens, the cost-effectiveness and budget impacts of bringing more DAAs into the reimbursement lists are also addressed. Several small-scale targeted literature searches were conducted in PubMed for various topics covered in the article, and hand searching was performed to fill any data gaps. More recent data were used wherever possible. Expert opinion: Considering the unique socioeconomical landscape of China, micro-elimination strategies might be more effective and should be targeted at high-risk populations. Varying regional needs in HCV care across the country necessitate decentralized approaches in research and policy-making.

Entities:  

Keywords:  Direct-acting antiviral; epidemiology; hepatitis C; micro-elimination

Mesh:

Substances:

Year:  2019        PMID: 31578079     DOI: 10.1080/14787210.2019.1675509

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  7 in total

Review 1.  Feasibility of Hepatitis C Elimination in China: From Epidemiology, Natural History, and Intervention Perspectives.

Authors:  Zeyu Zhao; Meijie Chu; Yichao Guo; Shiting Yang; Guzainuer Abudurusuli; Roger Frutos; Tianmu Chen
Journal:  Front Microbiol       Date:  2022-06-02       Impact factor: 6.064

2.  Hepatitis C Prevalence, Incidence, and Treatment in Chinese Hemodialysis Patients: Results From the Dialysis Outcomes and Practice Patterns Study-China (2019-21).

Authors:  Liangying Gan; Dongyu Wang; Brian Bieber; Keith McCullough; Michel Jadoul; Ronald L Pisoni; Fanfan Hou; Xinling Liang; Zhaohui Ni; Xiaonong Chen; Yuqing Chen; Li Zuo
Journal:  Front Med (Lausanne)       Date:  2022-06-15

3.  Crowdsourcing to promote hepatitis C testing and linkage-to-care in China: a randomized controlled trial protocol.

Authors:  William C W Wong; Nancy S Yang; Jingjing Li; Hang Li; Eric Y F Wan; Thomas Fitzpatrick; Yuan Xiong; Wai-Kay Seto; Polin Chan; Ruihong Liu; Weiming Tang; Joseph D Tucker
Journal:  BMC Public Health       Date:  2020-07-02       Impact factor: 3.295

Review 4.  Eliminate Hepatitis C as a Public Health Threat: A Narrative Review of Strategies, Gaps, and Opportunities for China.

Authors:  Yuanyuan Song; Yuchang Li; Hanchao Cheng; Xinyu Du; Jiarun Mi; Linh-Vi Le; Zhongdan Chen; Polin Chan; Jing Sun
Journal:  Infect Dis Ther       Date:  2022-07-11

5.  A randomized controlled trial enhancing viral hepatitis testing in primary care via digital crowdsourced intervention.

Authors:  William C W Wong; Gifty Marley; Jingjing Li; Weihui Yan; Po-Lin Chan; Joseph D Tucker; Weiming Tang; Yuxin Ni; Dan Dan Cheng; Lou Cong; Wai-Kay Seto
Journal:  NPJ Digit Med       Date:  2022-07-19

6.  Pharmacokinetics, Safety, and Tolerability of Ravidasvir, with and without Danoprevir/Ritonavir, in Healthy Subjects.

Authors:  Guolan Wu; Huili Zhou; Jing Wu; Duo Lv; Lihua Wu; You Zhai; Meihua Lin; Jingzi J Wu; Jianzhong Shentu
Journal:  Antimicrob Agents Chemother       Date:  2021-07-12       Impact factor: 5.191

7.  A study based on four immunoassays: Hepatitis C virus antibody against different antigens may have unequal contributions to detection.

Authors:  Xinyi Jiang; Le Chang; Ying Yan; Huimin Ji; Huizhen Sun; Fei Guo; Lunan Wang
Journal:  Virol J       Date:  2021-07-03       Impact factor: 4.099

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.